Insulet Corp is a healthcare company specializing in the development and manufacturing of innovative insulin delivery systems for individuals with diabetes. The company is best known for its Omnipod Insulin Management System, a tubeless, waterproof device that allows users to deliver insulin discreetly and conveniently without the need for traditional syringes or infusion sets. Insulet is committed to enhancing the quality of life for diabetes patients by providing advanced technology solutions that simplify insulin management, improve glycemic control, and promote independence in self-care. Through ongoing research and development, Insulet aims to lead the way in diabetes management innovation. Read More
-link data-ticker=GOOGL data-exchange=NASDAQ href=https://www.benzinga.com/quote/GOOGL target=_blank rel=noopener>(NASDAQ: GOOGL), One week after we celebrated the International Women's day, here is a stark reminder how the C-suite remains underrepresented by women.Data from a leadership-focused ETF underscores how uncommon female leadership remains among large U.S. companies. The Wedbush ReturnOnLeadership U.S. Large-Cap ETF (ARCA: EXEQ) universe of 50 companies, only about 10% are led by women CEOs. Those include Jayshree Ullal of Arista Networks Inc (NYSE: ANET), Lori Koch of DuPont de Nemours Inc (NYSE: DD), Martina Cheung of S&P Global Inc (NYSE: SPGI), Ashley McEvoy of Insulet Corp (NASDAQ: PODD) and Debra Cafaro of Ventas Inc (NYSE: VTR). The ETF tracks companies ranked through a leadership execution framework developed by Indiggo. Janeen Gelbart, co-founder and CEO of the firm, said the methodology evaluates corporate leadership broadly rather than focusing on individual executives.
Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Insulet Corporation (“Insulet” or the “Company”) (NASDAQ: PODD) investors concerning the Company’s possible violations of the federal securities laws.
Law Offices of Howard G. Smith announces an investigation on behalf of Insulet Corporation (“Insulet” or the “Company”) (NASDAQ: PODD) investors concerning the Company’s possible violations of federal securities laws.
The Law Offices of Frank R. Cruz announces an investigation of Insulet Corporation (“Insulet” or the “Company”) (NASDAQ: PODD) on behalf of investors concerning the Company’s possible violations of federal securities laws.
Insulet Corporation (NASDAQ: PODD) (“Insulet” or the “Company”) today initiated a voluntary Medical Device Correction for specific lots of Omnipod® 5 Pods after identifying a manufacturing issue through its ongoing product monitoring. This action applies to specific identified lots distributed in the United States, and all other Omnipod® 5 Pods and Omnipod® products remain safe to use.
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, has shared new clinical evidence related to the development of its first fully closed-loop (FCL)A automated insulin delivery (AID) system for type 2 diabetes.
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, will present new clinical evidence related to its first fully closed-loop (FCL) automated insulin delivery (AID) system for type 2 diabetes (T2D) at the 19th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD), taking place March 11 – 14, 2026 in Barcelona, Spain, and online.
Hitting a new 52-week low can be a pivotal moment for any stock.
These floors often mark either the beginning of a turnaround story or confirmation that a company faces serious headwinds.
Insulin delivery company Insulet Corporation (NASDAQ:PODD) reported Q4 CY2025 results exceeding the market’s revenue expectations, with sales up 31.2% year on year to $783.8 million. The company expects next quarter’s revenue to be around $716.9 million, close to analysts’ estimates. Its non-GAAP profit of $1.55 per share was 6% above analysts’ consensus estimates.
Shares of insulin delivery company Insulet Corporation (NASDAQ:PODD) jumped 5.6% in the afternoon session after the company posted strong fourth-quarter 2025 financial results that beat Wall Street's expectations.
Insulet Corporation (NASDAQ:PODD) delivered a commanding performance in its fourth-quarter earnings report released today, February 18, 2026. The medical device leader announced an adjusted earnings per share (EPS) of $1.55, significantly outstripping Wall Street’s consensus estimate of $1.46. Revenue for the quarter reached $783.8 million,
Insulin delivery company Insulet Corporation (NASDAQ:PODD) reported revenue ahead of Wall Street’s expectations in Q4 CY2025, with sales up 31.2% year on year to $783.8 million. The company expects next quarter’s revenue to be around $716.9 million, close to analysts’ estimates. Its non-GAAP profit of $1.55 per share was 6% above analysts’ consensus estimates.
